Aerie touts late-stage safety data for Roclatan eye drops

Aerie Pharmaceuticals (NSDQ:AERI) touted 12-month safety data yesterday from the Phase III registration trial of its Roclatan eye drops for intraocular pressure resulting from glaucoma or ocular hypertension.
The study was designed to support Aerie’s new drug application submission to the FDA for Roclatan, which it expects to file in the first half of next year.
Get the full story at our sister site, Drug Delivery Business News.
The post Aerie touts late-stage safety data for Roclatan eye drops appeared first on MassDevice.

Source: Mass Device - July 21, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Wall Street Beat Aerie Pharmaceuticals Source Type: news